The content on this site is intended for healthcare professionals only
Dr Mendelsohn speaks with ecancer at AACR 2017 about the aims of the WIN Consortium.
He introduces the rationale of the annual conference, with key speakers on the latest in personalised therapy coming from around the world to discuss current practice and next steps.
Dr Mendelsohn highlights the theme of this years conference as bringing the latest understandings of biomarkers and personalised care to clinical readiness, and encourages ongoing efforts in refining approaches and delivery of care.
He highlights greater understanding of cell death pathways as offering novel opportunities in understanding diseases and therapies, and ongoing research into personalised therapy for varying populations.
For more about the WIN consortium click here, or watch interviews from last year's symposium here.
The added value of integrative medicine
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Social determinants of health in primary care
The current status of multiple myeloma diagnosis and treatment
